sfondo pallini

Luca Benatti, President and Chief Executive Officer, and Stan Musial, Chief Financial Officer, will participate in the JMP Life Sciences Conference

close button

June 10, 2019

Download pdf logo twitter logo linkedin

Bresso (Milano), Italy – June 10, 2019 – EryDel SpA, a biotech company specialized in the development of drugs and diagnostics delivered through autologous red blood cells, today announced that Luca Benatti, President and Chief Executive Officer, and Stan Musial, Chief Financial Officer, will participate in the JMP Life Sciences Conference on Wednesday, June 19, 2019, at the St. Regis New York. The Company is scheduled to present at the conference at 1:30 p.m. ET the same day.

A live audio webcast of the conference presentation will be available online at http://wsw.com/webcast/jmp39/erd/. A replay of the webcast will be archived on the website for approximately 90 days.

About EryDel EryDel SpA
is a biotechnology company specialized in the development of drugs delivered through red blood cells (RBCs) by using a proprietary medical device technology. Its most advanced product, EryDex System (EDS) is under late stage development for the treatment of Ataxia Telangiectasia, a rare autosomal recessive disorder for which no established therapy is currently available. EryDex has received Orphan Drug designation for the treatment of AT both from the FDA and the EMA. A completed pilot Phase II trial in AT patients demonstrated statistically significant efficacy of EDS on both the primary and secondary efficacy measures. An international multi-center, Phase III pivotal study, ATTeST, is being conducted. EryDel has a pipeline of preclinical programs that use its proprietary RBC’s delivery technology for the treatment of other rare diseases.

About Ataxia Telangiectasia
Ataxia Telangiectasia (AT) is a rare genetic disease caused by biallelic mutations in the ataxia telangiectasia mutated (ATM) gene, for which no established therapy is currently available. ATM encodes a PI3Kinase protein shown to play a pivotal role in response to DNA damage and cell cycle control. Homozygosity for ATM mutations result in a multi-systemic disorder, involving mainly the nervous and immune systems. The major clinical feature of AT is severe progressive neurodegeneration from early infancy. Specific features include progressive ataxia of the trunk and limbs, involuntary movements, oculomotor apraxia, difficulties with speech and swallowing, and delayed peripheral neuropathy. Other clinical features of patients with the classical phenotype include oculocutaneous telangiectasia, immunodeficiency with recurrent respiratory tract infections, radiosensitivity and an increased incidence of cancer.

Investor Contact:
Stan Musial
Chief Financial Officer
Stan.musial@erydel.com